# GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/glp1-low-blood-sugar-risk

> A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.

## Key points

- GLP-1s act glucose-dependently, so alone they rarely drive sugar too low.
- The BMJ network meta-analysis names sulfonylureas, insulin and DPP-4 inhibitors, not GLP-1s.
- The label counted one severe episode requiring another person’s assistance, against none on placebo.
- Use in type 1 diabetes, or with insulin, “has not been evaluated”, which means untested, not prohibited.

If a GLP-1 is the only glucose-lowering drug you take, low blood sugar is an unlikely problem. These drugs prompt insulin release *in response to* glucose, so when glucose is not high they largely stop prompting. The risk arrives with what sits beside them. The Wegovy label is explicit about which company it keeps: put a sulfonylurea, or insulin, in the picture and hypoglycemia becomes more likely. It tells prescribers to consider cutting that other dose at the point the GLP-1 starts.[1] Metformin is not on that list; where it does overlap with a GLP-1 is covered in [metformin and a GLP-1 together](https://glpwatchdog.org/research/metformin-and-a-glp1-together).

## Why the mechanism matters here

Insulin, and the sulfonylureas the label groups as insulin secretagogues, lower blood glucose whether or not it needs lowering. That is what makes them capable of driving it too far down. A GLP-1 works differently: its effect on insulin secretion is glucose-dependent, which is the technical way of saying it largely stands down when glucose is normal.

The largest ongoing comparison of diabetes medicines, a living network meta-analysis in the BMJ updated at least twice a year, reflects that. It names sulfonylureas, insulin and DPP-4 inhibitors as probably increasing the risk of severe hypoglycemia.[2] GLP-1 receptor agonists are not in that list. In one trial, swapping basal-bolus insulin for a [weekly semaglutide and insulin icodec injection](https://glpwatchdog.org/research/one-injection-instead-of-twenty-eight) cut serious lows by 88%. (Why a DPP-4 inhibitor such as Januvia is usually stopped when a GLP-1 starts is set out in [Januvia and a GLP-1 together](https://glpwatchdog.org/research/januvia-and-a-glp1-together).)

> Insulin and sulfonylureas lower blood glucose whether or not it needs lowering; a GLP-1 largely stands down when glucose is normal.

## What the label actually counted

“Unlikely” is not “never”, and the label does not pretend otherwise. In its trial of adults who had type 2 diabetes alongside a BMI of 27 or above, hypoglycemia (defined as plasma glucose below 54 mg/dL) was reported in more patients on Wegovy than on placebo. One episode of **severe** hypoglycemia, meaning it required another person’s help, occurred in a treated patient, against none on placebo.[1]

One episode is a small number, but it is not zero, and it comes from the population where this matters: people who have diabetes as well as excess weight, and who are therefore likely to be on other glucose-lowering drugs already.

> **If you do not have diabetes and take nothing else for glucose, this page is mostly reassurance.** The trials in that population do not show meaningful hypoglycemia, and the mechanism explains why. Learn the symptoms anyway, and come back to this the moment any other glucose-lowering drug is added. An over-the-counter glucose sensor will not warn you of a low; see [what CGMs can and cannot do without diabetes](https://glpwatchdog.org/research/cgm-for-weight-loss-without-diabetes).

## The combination the label has not tested

One sentence in the label is easy to read past. It states that the use of Wegovy in patients with [type 1 diabetes](https://glpwatchdog.org/research/glp1-and-type-1-diabetes), or in combination with insulin, **has not been evaluated**.[1]

That is not a contraindication or a warning against it. It means untested, and the difference matters because people reasonably assume that an approved drug has been studied in the combination they are personally taking. The sentence is about Wegovy’s own trials, though, not the whole class. Someone taking Wegovy with insulin is outside what those trials examined, whatever their prescriber has concluded is right for them. At diabetes doses the combination has been studied: the Ozempic and Mounjaro labels each report a trial that added the drug to basal insulin in type 2 diabetes, with hypoglycemia counted.[3][4]

## What the label asks a prescriber to do

1. **Check glucose before starting, and during.** For patients with diabetes the label asks for monitoring at both points, not just afterward.[1]
2. **Consider a smaller dose of the sulfonylurea or insulin from the day the GLP-1 begins.** The label frames this as something to weigh when the GLP-1 starts, rather than a change to make after a low reading.[1]
3. **Teach the symptoms.** The label asks prescribers to inform patients of the risk and educate them on the signs, which implies you should have been told and can ask if you were not.

> **We are not going to tell you how much to reduce anything by.** The label says “consider reducing” without naming a figure, because it depends on which drug, what dose, and your own readings. That is a prescriber’s judgment, and it is the conversation to have before the first GLP-1 injection rather than after the first low reading. Our [titration planner](https://glpwatchdog.org/tools/glp1-titration-planner) will print your drug’s own schedule so you can take a dated plan into that appointment.

## Knowing it when it happens

Shakiness, sweating, a racing heart, sudden hunger, confusion, irritability or difficulty concentrating. During sleep it can show up as nightmares or damp sheets instead; see [GLP-1s and nightmares](https://glpwatchdog.org/research/glp1-vivid-dreams-and-nightmares). Severe episodes can progress to an inability to treat yourself, which is what the label means by requiring another person’s assistance. A racing heart without those other signs has other explanations on these drugs, covered in [GLP-1 heart rate and palpitations](https://glpwatchdog.org/research/glp1-heart-rate-and-palpitations). Because the labels list anxiety among these signs, an episode can be mistaken for a panic attack; see [GLP-1s and anxiety](https://glpwatchdog.org/research/glp1-and-anxiety).

There is a wrinkle specific to these drugs. GLP-1 medicines slow how quickly the stomach empties, which is also how quickly a fast-acting carbohydrate reaches the bloodstream. That does not change what you should do about a low reading, but it is a reason to raise the question with whoever manages your diabetes, since the usual timing assumptions may not hold. A fast long enough to matter changes that arithmetic, and the only place it has been studied is Ramadan. [What the four Ramadan studies actually tested](https://glpwatchdog.org/research/glp1-during-ramadan) is narrower than it is usually reported to be.

## Frequently asked questions

### Can Wegovy or Ozempic cause low blood sugar?

On their own, rarely. These drugs prompt insulin release in response to glucose, so the effect largely stands down when glucose is normal. The label still counted hypoglycemia below 54 mg/dL in more treated patients than placebo in its type 2 diabetes trial, including one severe episode requiring another person's assistance.

### What if I also take insulin or a sulfonylurea?

That is where the risk is. The label records a higher rate of hypoglycemia once a sulfonylurea or insulin is also being taken, asks prescribers to weigh a reduction in that other dose as the GLP-1 begins, and asks for glucose monitoring both before and during treatment.

### Is a GLP-1 safe with type 1 diabetes?

The label does not say it is unsafe; it says the use of Wegovy in type 1 diabetes, or in combination with insulin, has not been evaluated. That is untested rather than prohibited, and it means anyone in that situation is outside what Wegovy's own trials examined. Ozempic and Mounjaro, at diabetes doses, were tested added to basal insulin in type 2 diabetes.

### Should I lower my insulin dose when starting a GLP-1?

Possibly, but only your prescriber can say by how much. The label asks them to consider a reduction at initiation without naming a figure, because it depends on the drug, the dose and your own readings. Raise it before the first injection rather than after a low reading.

### Does slowed stomach emptying change how I treat a low?

It may affect timing, since these drugs slow how fast the stomach empties and therefore how fast a fast-acting carbohydrate is absorbed. It does not change that a low needs treating. Ask whoever manages your diabetes how it changes the usual advice for you.

## References

1. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 5.4 Hypoglycemia and Section 7.1 Drug Interactions (revised 06/2026). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Nong K, Jeppesen BT, Shi Q, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025. PMID: 40813122. https://pubmed.ncbi.nlm.nih.gov/40813122/
3. Novo Nordisk Inc. OZEMPIC (semaglutide) injection: US Prescribing Information, Sections 6.1 and 14 (combination with basal insulin). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
4. Eli Lilly and Company MOUNJARO (tirzepatide) injection: US Prescribing Information, Sections 6.1 and 14 (SURPASS-5, added to basal insulin). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0

---

Cite as: GLP Watchdog, Ruth Calder, "GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk", published 2026-08-19, updated 2026-11-01. https://glpwatchdog.org/research/glp1-low-blood-sugar-risk

Canonical HTML page: https://glpwatchdog.org/research/glp1-low-blood-sugar-risk

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
